Da Vinci's Vitruvian Man Encodes the Blueprint of Human Evolution, Says London Dentist
LONDON, July 14, 2025 (GLOBE NEWSWIRE) — A London-based dental surgeon and researcher, Dr. Rory Mac Sweeney of Precision Endodontics, has ignited international interest with a provocative reinterpretation of Leonardo da Vinci's Vitruvian Man. His newly published research suggests the Renaissance masterpiece encodes a precise geometric ratio that reflects the biomechanical endpoint of human evolution.
Dr. Mac Sweeney's theory, published in the Journal of Mathematics and the Arts, identifies a hidden equilateral triangle embedded in Vitruvian Man. He connects this geometry to Bonwill's Triangle—a fundamental dental structure first described in the 19th century, which governs optimal jaw alignment and function. According to Mac Sweeney, this triangular structure appears throughout the body and is mathematically anchored by the ratio √8/3, or approximately 1.633.
'Leonardo's drawing isn't just a study in proportion—it's a map of tension,' said Dr. Mac Sweeney. 'The 1.633 ratio appears in the jaw, the spine, and the skull. It reflects a state known as vector equilibrium, where structural tension and compression are perfectly balanced. I believe this marks the final step in the human journey toward full upright posture.'
This ratio, derived from the geometry of the cuboctahedron, is widely recognized in biomechanics and architecture as a hallmark of tensegrity—the balance of forces within a stable form. Dr. Mac Sweeney contends that this geometry defines the Vitruvian Morphotype: a form that nature has converged on through evolutionary pressures—not because it is aesthetically pleasing, but because it is structurally optimal.
'Human evolution has been a long progression toward uprightness,' he explained. 'The 1.633 ratio may represent our evolutionary omega point—a structural threshold beyond which no further anatomical adaptation is needed to stand, move, and balance efficiently in gravity.'
Mac Sweeney suggests that fossil evidence should reveal a slow convergence toward this geometric configuration, particularly in the jaw. He highlights the emergence of Class I occlusion in the fossil record—also known as the overbite/overjet 'step'—around 8,000 years ago as a key moment. While small variations remain, he argues that modern Homo sapiens are the first species to fully express this morphotype.
'It's like the hydrodynamic form of a dolphin,' he said. 'Nature solves gravity the way it solves water. Vitruvian Man is the first full sketch of what that solution looks like.'
Dr. Mac Sweeney's theory is now attracting attention from experts in evolutionary biology, bioengineering, and anatomical design. He is currently conducting interviews, public talks, and media appearances to discuss what he calls the Vitruvian Ratio—and its broader implications for anthropology, architecture, and even consciousness.
'Leonardo, somehow, saw it coming,' Mac Sweeney added. 'Vitruvian Man may be the only anatomical diagram ever created that captures not just what a human is—but what a human is becoming.'
About Dr. Rory Mac Sweeney:
Dr. Mac Sweeney is a London-based endodontist and researcher known for his interdisciplinary work in dental anatomy, geometry, and human evolution. His work explores the convergence of structural biology and classical design, and he is the author of the book The Paradox of Lucid Dreaming. @luciddreamyoga
Contact Information:
Contact person: Dr. Rory Mac SweeneyCompany name: Precision EndodonticsWebsite: [www.precisionendodontics.co.uk]
Press Contact: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
If you have a high VO2 max score, you could live longer. I took a class to boost mine — and finally found a way to make cardio fun.
VO2 max is a buzzy measure of heart health and fitness. I tried a class that promised to boost my VO2 max through cardio and breathwork. I don't typically do cardio, and I realized taking classes could help me make it a habit. I have a strange question, but stay with me: Have you ever thought about how long you can run without breathing through your mouth? In a dark basement in central London I recently discovered that, for me, the answer is: Not for very long. Apparently, that means my VO2 max, or ability to send oxygenated blood to my muscles, and how well my muscles can use that oxygen during intense exercise, is quite low. Translation: I'm unfit. I do low-impact strength training like yoga and pilates most days, but no cardio. I've tried to get into running, but it never sticks, and I find cardio machines boring. I learned specifically how bad I am at cardio at V02:MAXED, a new class at London's GymBox. I knew one session wouldn't transform my health, but I was interested to try the first class I'd seen marketed around VO2 max. I wondered if exercising with a specific goal might motivate me to finally form a cardio habit, and if the class — and the nose strips we had to wear while working out — was just a fad. Once the preserve of high-level athletes, in recent years, VO2 max has become a buzzy measure of cardiovascular fitness among runners, fitness competition enthusiasts, and health optimization bros. People are obsessed with it because it's said to be a strong predictor of longevity. As I'm not an endurance athlete, my low score may not seem like a big deal, but having a high VO2 max is linked to a longer life, and a reduced risk of conditions including cardiovascular disease, cancer, and diabetes. I don't care that I can't run five kilometers in under 30 minutes, but I do care about staying active and healthy as I age. To increase your VO2 max, you have to do a mixture of shorter high-intensity and longer, easier workouts. VO2:Maxed is a 16-week course where clients train at a range of intensities. The class I did was the fourth in the series. Feeling nervous about entering a gym that uses the words "gnarly," "sadistic," and "savage" to describe some of its classes, I descended the staircase from the reception area to the dimly lit bodybuilder's playground below with trepidation. In the 50-minute class, we repeated three-minute sets on a stroke machine (ski or rower) and a cycle machine (bike or treadmill), with 45-second breaks in between. I used a ski machine and an assault bike. What made the class unique was the breathwork. Our instructor, Firas Iskandarani, a Hyrox and Crossfit coach, explained that we should aim to breathe through our noses for most of the class. He called this type of breathing "gear one," and breathing in through the nose and out through the mouth "gear two." We were told to note when we had to "switch gears." Iskandarani said this should happen after around 90-seconds to two-minutes, but I struggled to get to one minute. As a rough guide, the longer you can stay in gear one, the higher your VO2 max is likely to be, he said. The idea is that, over time, you will need to switch gears less quickly, which indicates your aerobic capacity has increased. About halfway through the class, we were given nasal strips to stick on the fleshy part of our noses, and encouraged to notice if it helped us stay in gear one for longer. It's thought that widening the nasal canal could help to increase endurance by allowing more air through the nose. But one 2020 meta-analysis published in the European Archives of Oto-Rhino-Laryngology found that wearing a nasal strip while exercising didn't improve VO2 Max or heart rate. Still, lots of runners and athletes swear by them, like the elite tennis player Carlos Alcaraz, who wears them during his matches. I felt that the nasal strip helped a little, but it kept peeling off as my nose got sweaty. Nasal breathing is not directly linked to improving VO2 max, but is thought to help the body use oxygen more efficiently. It also encourages you to stay in Zone 2, or at 60-70% of your maximum heart rate, while you're exercising. Your muscles have more access to oxygen in Zone 2, making it an effective way to increase aerobic endurance. Once you enter Zone 3, 70% to 80% of your max heart rate, you're moving at an intensity that's too much for the available oxygen supply, which causes you to get out of breath. I found there was a lot to remember and focus on in this class: not only understanding the different gears, but trying to stay in gear one while checking the clock to see when I started mouth breathing. All of this mental arithmetic was required on top of the three-minute sets of cardio, which, I think is fair to say, is a long time. My mind kept wandering and I kept accidentally mouth breathing before I'd actually reached my threshold. It was also tricky to go at a slow enough pace to stay in gear one for even a minute. After about thirty seconds I started to lose my breath. I suppose that tells me I have some work to do in this area. That being said, I wasn't huffing and puffing or red in the face afterwards like I usually am after a 35-minute run. But my arms did get very tired from pulling the ropes on the ski machine and moving the handles on the assault bike back and forth. If I did this class again I would pace myself better so that I wouldn't get out of breath so quickly. But I think for a cardio beginner like me, it was a little too technical and advanced. Iskandarani said that part of the demand for the class came from Hyrox fans and CrossFitters, who are already pretty fit and looking to increase their endurance for competitions. But I found doing cardio in such a structured way and with a group of people much more fun and motivating than doing it alone. Going forward, I think I'll stick to cardio classes rather than running every once in a while, getting bored, and trying again when enough time has passed for me to forget how arduous I found it. By focusing on my breath, it became apparent that my cardiovascular fitness is lower than I'd like, and I'm only 28. I wondered how it would inevitably deteriorate over time, and if I'm struggling to get through a class like this now, it's only going to get harder when I'm in my 50s, let alone 80s. As for the VO2 max workout, I don't think it was the right cardio class for me, but it's motivated me to continue my search. Anyone for Zumba? Read the original article on Business Insider
Yahoo
4 hours ago
- Yahoo
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. New York, USA, July 15, 2025 (GLOBE NEWSWIRE) -- Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain. Key Takeaways from the Endometrial Cancer Pipeline Report DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs. Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape. Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials. In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers. In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed. In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer. In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer. In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS). Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape. Endometrial Cancer Overview Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success. Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk. Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment. Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient out more about endometrial cancer drugs @ Endometrial Cancer Treatment A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report: Drugs Company Phase MoA RoA Selinexor Karyopharm Therapeutics III Exportin 1 protein inhibitors Oral EG-007 Evergreen Therapeutics III Epidermal growth factor receptor antagonists Injectable Abemaciclib Eli Lilly and Company II Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors Oral Envafolimab Alphamab Oncology/Ascletis/3D Medicine II Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants Subcutaneous Sirexatamab (DKN-01) Leap Therapeutics II DKK1 protein inhibitors Intravenous NP137 NETRIS Pharma II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous COM 701 Compugen I/II Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants Intravenous XMT-1660 Mersana Therapeutics I Tubulin inhibitors Intravenous Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials Endometrial Cancer Therapeutics Assessment The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Endometrial Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists Key Endometrial Cancer Companies: Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others. Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs Table of Contents 1. Endometrial Cancer Pipeline Report Introduction 2. Endometrial Cancer Pipeline Report Executive Summary 3. Endometrial Cancer Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Endometrial Cancer Clinical Trial Therapeutics 6. Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration) 7. Endometrial Cancer Pipeline: Late-Stage Products (Phase III) 8. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II) 9. Endometrial Cancer Pipeline: Early-Stage Products (Phase I) 10. Endometrial Cancer Pipeline Therapeutics Assessment 11. Inactive Products in the Endometrial Cancer Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Endometrial Cancer Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics Related Reports Endometrial Cancer Epidemiology Forecast Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometrial Cancer Market Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others. Advanced Endometrial Cancer Pipeline Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others. Endometriosis Pipeline Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
Medscape
4 hours ago
- Medscape
5 Fast Facts: Plant Extracts Relieve Hand Osteoarthritis
If you have patients with hand osteoarthritis (OA) who want extra relief and don't mind trying a plant-based supplement, this combo looks promising. Researchers in Belgium found that a daily combination of plant extracts significantly reduced hand OA pain over time. 1. Patients had real pain relief. People with hand OA who took Curcuma longa (turmeric) and Boswellia serrata had noticeably better pain reduction over 3 months than those on placebo, about 8-9 points better on the pain scale. 2. Quality of life received a boost, too. Patients didn't just feel less pain; they also reported feeling better overall and rated their quality of life higher than the placebo group. 3. Safe and easy to stick with. Patients took the supplement consistently (over 90% adhered to it), and side effects were comparable to those of the placebo. 4. Well-done study — but with a few limits. This solid randomized, double-blind, placebo-controlled trial focused on patient-reported outcomes rather than structural improvements or radiographic findings. 5. Another option for the toolbox. These extracts aren't a replacement for standard care, but they may be a safe adjunct for patients wanting complementary therapies for hand OA pain, especially those who prefer more 'natural' options. Bottom line: Current evidence indicates that plant extracts provide symptomatic relief for hand OA; however, they do not address the underlying joint pathology. Counsel patients on these limitations.
